Laser vs Ozone Therapy for Oral Mucositis in Cancer Patients
Launched by UNIVERSITY OF PAVIA · Jul 5, 2025
Trial Information
Current as of July 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different treatments—laser therapy and ozone therapy—to help reduce the pain and mouth sores caused by oral mucositis, a common side effect of cancer treatments like chemotherapy and radiation. Oral mucositis causes painful ulcers in the mouth that can make eating, speaking, and keeping the mouth clean very difficult. The study aims to find out which treatment works better to ease these symptoms and improve patients’ quality of life.
Adults with head and neck cancer or blood cancers who are currently receiving chemotherapy or radiation and have moderate to severe mouth sores may be eligible to join. If you participate, you will be randomly assigned to receive either laser therapy or ozone therapy once a day for five days. The treatments are painless and done using special devices inside the mouth. You will be checked at 15 and 30 days after starting treatment to see how well the sores and pain have improved. The study will also look at how these treatments affect your overall comfort and daily life during cancer care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Diagnosis of head and neck cancer or hematologic malignancy
- • Currently undergoing chemotherapy and/or radiotherapy
- • Presence of oral mucositis of grade 2 or higher (WHO Oral Mucositis Scale)
- • Ability to provide written informed consent
- • Willingness to comply with study procedures and follow-up schedule
- Exclusion Criteria:
- • Presence of autoimmune or systemic diseases affecting the oral mucosa (e.g., lichen planus, pemphigus, pemphigoid)
- • Presence of active oral infections unrelated to mucositis (e.g., candidiasis, herpes simplex)
- • Previous treatment with ozone or laser therapy for oral mucositis in the past 3 months
- • Pregnancy or breastfeeding
- • Cognitive impairment or psychiatric disorders preventing full cooperation
- • Known allergy or intolerance to ozone or laser exposure
- • Use of investigational drugs or participation in other clinical trials within 30 days prior to enrollment
About University Of Pavia
The University of Pavia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a prominent clinical trial sponsor. With a strong emphasis on advancing medical knowledge and improving patient care, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research. Collaborating with leading healthcare professionals and institutions, the University of Pavia is dedicated to exploring novel therapeutic approaches and fostering the translation of scientific discoveries into clinical practice, ultimately aiming to enhance health outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, Lombardy, Italy
Patients applied
Trial Officials
Andrea Scribante, Associate Professor
Principal Investigator
University of Pavia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported